Rasuvo and Heart attack - a phase IV clinical study of FDA data

Summary:

Heart attack is reported as a side effect among people who take Rasuvo (methotrexate), especially for people who are female, 60+ old, also take Humira, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Heart attack when taking Rasuvo. It is created by eHealthMe based on reports of 3,515 people who have side effects when taking Rasuvo from the FDA, and is updated regularly.

What is Rasuvo?

Rasuvo has active ingredients of methotrexate. It is often used in psoriatic arthritis. eHealthMe is studying from 3,702 Rasuvo users. Check the latest studies of Rasuvo.

What is Heart attack?

Heart attack is found to be associated with 2,482 drugs and 3,296 conditions by eHealthMe. Check the latest studies of Heart attack.

On Jul, 16, 2026

3,515 people reported to have side effects when taking Rasuvo.
Among them, 13 people (0.37%) have Heart attack.

Among these 13 people:

What is the gender of people who have Heart attack when taking Rasuvo? *

female: 61.54 %
male: 38.46 %

What is the age of people who have Heart attack when taking Rasuvo? *

What are other drugs people take besides Rasuvo? *

What are other side effects people have besides Heart attack? *

Joint Pain: 5 people, 38.46%
Mobility Decreased (ability to move is reduced): 4 people, 30.77%
Scrotal Cyst (cyst of scrotum): 3 people, 23.08%
Pneumonia: 3 people, 23.08%
Hepatic Enzyme Increased: 3 people, 23.08%
Hepatic Steatosis (fatty liver disease): 3 people, 23.08%
Psoriasis (immune-mediated disease that affects the skin): 3 people, 23.08%
Injection Site Pain: 2 people, 15.38%
Fatigue (feeling of tiredness): 2 people, 15.38%
Haemoglobin Decreased: 2 people, 15.38%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 10 people, 76.92%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 23.08%
Pain: 1 person, 7.69%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 7.69%
Cardiac Disorder: 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Rasuvo and have Heart attack?

- Check whether Heart attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rasuvo:

Rasuvo (3,702 reports)

Heart attack treatments and more:

Heart attack (266,145 reports)

Browse all side effects of Rasuvo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Heart attack:

Heart attack (2,482 drugs)

Browse all the conditions that are associated with Heart attack:

Heart attack (3,296 conditions)

Related publications that referenced our studies

Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on methotrexate (the active ingredients of Rasuvo) and Rasuvo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.